CYTK Cytokinetics, Incorporated
Legal ·
Cytokinetics (Nasdaq: CYTK) filed a complaint on August 13, 2026, seeking a declaratory judgment that it does not infringe U.S. Patent No. 12,616,697 and that the patent's claims are invalid. The defendants are Bristol-Myers Squibb and MyoKardia.
Cytokinetics issued $750.0 million of 1.75% convertible senior notes due 2031 on September 19, 2025, and expects to spend about $402.5 million of the net proceeds on the cash side of exchanges for its 2027 notes. The notes convert at about $68.42 a share. Neither the 8-K nor the release gives the company's cash balance.
Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors for diseases in which muscle performance is compromised. Its first commercial product, MYQORZO (aficamten), was approved by the FDA in December 2025 for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and became available for prescription on or around January 27, 2026. MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity, and its FDA approval includes a risk evaluation and mitigation strategy (REMS). The European Commission approved MYQORZO in February 2026, and China's National Medical Products Administration approved it in December 2025. The pipeline includes ACACIA-HCM, a Phase 3 trial evaluating aficamten in nHCM, and omecamtiv mecarbil, which is being evaluated in symptomatic heart failure with severely reduced ejection fraction in the COMET-HF study. Two earlier-stage candidates are ulacamten, for a subgroup of patients with symptomatic HFpEF with hypercontractility, and CK-089, with potential application to a specific type of muscular dystrophy. Cytokinetics has licensing agreements with Sanofi in China and Bayer in Japan.
| Product or program | What it is | Stage |
|---|---|---|
| MYQORZO (aficamten) | Cardiac myosin inhibitor for symptomatic oHCM | approved by FDA, European Commission and China NMPA |
| Aficamten in nHCM | Evaluated in the ACACIA-HCM trial | Phase 3 |
| Omecamtiv mecarbil | Evaluated for symptomatic heart failure with severely reduced ejection fraction | |
| Ulacamten | Candidate for a subgroup of patients with HFpEF with hypercontractility | clinical development |
| CK-089 | Candidate for a specific type of muscular dystrophy | clinical development |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $416.0 million | $339.4 million |
| Net income (loss) | -$785.0 million | -$589.5 million |
| Cash from operations | -$510.0 million | -$395.9 million |
| Cash and equivalents | $122.5 million | $94.9 million |
| Short-term investments | $759.7 million | $981.2 million |
Our latest story on this, dated Sep 22, 2025: "Cytokinetics issues $750.0 million of 1.75% convertible senior notes due 2031". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 13, 2026: "Cytokinetics sues Bristol-Myers Squibb and MyoKardia in Delaware patent suit over MYQORZO". The story links the filing or release it is based on. Read the story.
Cytokinetics, Incorporated trades under the ticker CYTK on NASDAQ.
Cytokinetics, Incorporated is listed on NASDAQ. Our directory also records these other listings: DUS:KK3A; FWB:KK3A; GETTEX:KK3A; HAM:KK3A; HAN:KK3A; LS:A1W1KK; MUN:KK3A; SWB:KK3A; TRADEGATE:KK3A; XETR:KK3A.
The SEC Central Index Key (CIK) for Cytokinetics, Incorporated is 1061983. Its filings are on SEC EDGAR.
139,023,418 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Cytokinetics, Incorporated under United States.
Our directory classifies Cytokinetics, Incorporated as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Cytokinetics, Incorporated is US23282W6057.
aibio.space lists Cytokinetics, Incorporated among 2,820 public biotech companies and publishes its news here as stories appear.
Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors for diseases in which muscle performance is compromised. Its first commercial product, MYQORZO (aficamten), was approved by the FDA in December 2025 for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and became available for prescription on or around January 27, 2026.
MYQORZO (aficamten): Cardiac myosin inhibitor for symptomatic oHCM Stage: approved by FDA, European Commission and China NMPA.
Aficamten in nHCM: Evaluated in the ACACIA-HCM trial Stage: Phase 3.
Cytokinetics, Incorporated reported a net loss of $785.0 million for the fiscal year ended Dec 31, 2025, and used $510.0 million of cash in operations, per its annual report to the SEC.
$416.0 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio